广妇儿分享抗击儿童新冠“广东经验”:为世卫报告提供重要参考 研究成果在NATURE MEDICINE发表

2020-03-16 网络 网络

北京时间今天(3月13日)17时,广州市妇女儿童医疗中心临床研究团队在国际知名学术期刊《Nature Medicine》发表“新冠病毒感染患儿流行病学和临床特征分析及肠道持续排毒的证据探索

北京时间今天(3月13日)17时,广州市妇女儿童医疗中心临床研究团队在国际知名学术期刊《Nature Medicine》发表“新冠病毒感染患儿流行病学和临床特征分析及肠道持续排毒的证据探索(Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding)”研究论文,总结分析了市妇儿医疗中心在新冠肺炎疫情期间收治的10例确诊患儿的流行病学和临床特征,研究发现儿童病例中存在新冠病毒通过粪口传播的可能性,以及肛拭子核酸检测阳性较长时间存在、肠道排毒时间较长,该研究结果为儿童感染新冠病毒的临床诊治提供了重要参考,为儿童病例的确诊、治疗及康复观察提供了新的思路和方向。该研究数据在上线发表时同步向世界卫生组织汇报分享。

 

广州妇儿中心临床研究:新冠肺炎患儿肛拭子核酸检测阳性较长时间存在

 

新冠肺炎疫情中,广州市妇女儿童医疗中心作为广州地区儿童病例的定点医院,迄今为止已经收治了10例确诊患儿。

临床特征其一:肛拭子核酸检测阳性较长时间存在、肠道排毒时间较长。1月22日,市妇儿中心收治了广州首例新型冠状病毒感染确诊儿童病例。在治疗过程中,我院发现患儿肛拭子检测呈阳性、肠道排毒的时间更长,并在随访2月6日首位治愈患儿于居家医学观察期发现肛拭子复阳的问题。

临床特征其二:在无症状感染的情况下,CT较X光检查更能发现肺炎指征。2月初,我院起初采用床边X光的方式拍胸片检查患儿肺部感染情况,但结果多为无肺炎指征,与已知的疑似或确诊病例具有肺炎影像学特征的情况和患儿实际病程进展有出入,于是提出加做CT检查以进一步了解肺部病变。通过CT检查发现,十例中有五例患儿肺部出现感染,其中两例更发现大面积病灶,从而明确了CT优于X光的检查手段,以便保证患儿获得及时、对症的治疗。

临床特征其三:儿童病例多为家庭聚集性发病,症状为轻型、普通型甚至无症状感染等。经过不断积累临床经验并积极进行临床预测,临床团队不强调特殊用药,不主张过度医疗,并不断调整优化治疗方案,同时将相关信息及时反馈给广州市儿科研究所团队进行数据分析,总结儿童病例的临床特点,希望藉此协助其他儿童病例的诊疗工作。

参与制定广东省儿科专家共识,提交的修订要点被国家最新版诊疗方案采纳,汇报写入世卫组织联合考察报告

目前的结果对新冠病毒肺炎儿童病例的诊断、治疗提供了新的方法和思路。2月29日,《中国—世界卫生组织新型冠状病毒肺炎(COVID-19)联合考察报告》发布。该报告在提到儿童病例时指出:“联合考察组获悉,儿童病例多是通过追踪成人病例家庭密切接触者的时候发现的。值得注意的是,接受联合考察组访谈的人未发现有儿童传染成人的情况。”

而这正是广州市妇女儿童医疗中心医疗团队在2月20日对前来进行考察调研的世界卫生组织联合考察组所汇报的内容。

我院目前已参与制定了广东省儿童患者诊疗专家共识,提交的修订要点被国家最新版诊疗方案采纳。

如:

⊙增加了“由于在粪便及尿中可分离到新型冠状病毒,应注意粪便及尿对环境污染”的传播途径;

⊙增加儿童的临床表现描述“部分儿童及新生儿病例症状可不典型,表现为呕吐、腹泻等消化道症状或仅表现为反应差、呼吸急促。”;

⊙划分重型按照“成人”和“儿童”分别定义,根据国家儿科危重症的标准,增加儿童重型标准,增加儿童重型、危重型早期预警指标等。

临床与科研结合,让临床抗疫有术

广州妇儿医疗中心紧密协作的儿科临床研究体系

院方介绍,自新冠疫情发展以来收治确诊患儿的救治历程,是临床医学团队与基础科研团队互为协作的过程。临床与研究紧密结合、互相促进的特点得益于该院特有的儿科临床研究体系。

在此次疫情初现的第一时间,我院临床研究总监、中华预防医学会新型冠状病毒肺炎防控专家组成员唐金陵教授领导的团队加入到临床前线采集数据,提出问题和前线医生深入讨论并加以指导。

感染科徐翼主任带领的临床团队凭着对科研的高度敏锐度,基于临床的治疗观察形成经验,从个例中提炼特征,思考多个排毒路径的可能性并加以验证。

作为广东省首家开展新冠病毒核酸检测的医院,病毒实验室朱冰主任调动检测人员加班加点进行检测工作并将信息反馈给临床和研究团队。

临床数据中心梁会营博士团队和基础研究科学家合作进行数据分析,总结儿童病例的临床特点,助力临床治疗。

此次研究还得到广州市新型冠状病毒感染医疗救治儿科专家组组长龚四堂、基因检测中心主任张康及广东省儿童医学研究中心主任夏慧敏的组织及指导。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898531, encodeId=a930189853141, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Sep 12 09:28:43 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884164, encodeId=5cae1884164a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 17 09:28:43 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859035, encodeId=a566185903551, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Oct 30 01:28:43 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773840, encodeId=95051e73840cf, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 24 23:28:43 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577707, encodeId=af0b15e7707e2, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610338, encodeId=5d8f16103386c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027452, encodeId=89a7102e452fc, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Mar 16 12:28:43 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1898531, encodeId=a930189853141, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Sep 12 09:28:43 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884164, encodeId=5cae1884164a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 17 09:28:43 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859035, encodeId=a566185903551, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Oct 30 01:28:43 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773840, encodeId=95051e73840cf, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 24 23:28:43 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577707, encodeId=af0b15e7707e2, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610338, encodeId=5d8f16103386c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027452, encodeId=89a7102e452fc, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Mar 16 12:28:43 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
    2020-04-17 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1898531, encodeId=a930189853141, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Sep 12 09:28:43 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884164, encodeId=5cae1884164a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 17 09:28:43 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859035, encodeId=a566185903551, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Oct 30 01:28:43 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773840, encodeId=95051e73840cf, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 24 23:28:43 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577707, encodeId=af0b15e7707e2, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610338, encodeId=5d8f16103386c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027452, encodeId=89a7102e452fc, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Mar 16 12:28:43 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
    2020-10-30 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1898531, encodeId=a930189853141, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Sep 12 09:28:43 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884164, encodeId=5cae1884164a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 17 09:28:43 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859035, encodeId=a566185903551, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Oct 30 01:28:43 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773840, encodeId=95051e73840cf, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 24 23:28:43 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577707, encodeId=af0b15e7707e2, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610338, encodeId=5d8f16103386c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027452, encodeId=89a7102e452fc, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Mar 16 12:28:43 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
    2020-10-24 kalseyzl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1898531, encodeId=a930189853141, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Sep 12 09:28:43 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884164, encodeId=5cae1884164a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 17 09:28:43 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859035, encodeId=a566185903551, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Oct 30 01:28:43 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773840, encodeId=95051e73840cf, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 24 23:28:43 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577707, encodeId=af0b15e7707e2, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610338, encodeId=5d8f16103386c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027452, encodeId=89a7102e452fc, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Mar 16 12:28:43 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1898531, encodeId=a930189853141, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Sep 12 09:28:43 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884164, encodeId=5cae1884164a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 17 09:28:43 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859035, encodeId=a566185903551, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Oct 30 01:28:43 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773840, encodeId=95051e73840cf, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 24 23:28:43 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577707, encodeId=af0b15e7707e2, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610338, encodeId=5d8f16103386c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027452, encodeId=89a7102e452fc, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Mar 16 12:28:43 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1898531, encodeId=a930189853141, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sat Sep 12 09:28:43 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884164, encodeId=5cae1884164a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 17 09:28:43 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859035, encodeId=a566185903551, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Oct 30 01:28:43 CST 2020, time=2020-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773840, encodeId=95051e73840cf, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sat Oct 24 23:28:43 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577707, encodeId=af0b15e7707e2, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610338, encodeId=5d8f16103386c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Mar 18 00:28:43 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027452, encodeId=89a7102e452fc, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Mon Mar 16 12:28:43 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
    2020-03-16 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

广东首家中医互联网医院落户佛山

广东省佛山市中医院互联网医院24日正式启动,成为该省首家中医互联网医院。同日,佛山医保处方共享便民服务平台率先在该互联网医院试点,佛山市民未来可通过手机就能完成在线复诊、医保结算、快递送药上门或附近药店快速取药。

这些药,被广东卫健委推荐!奥司他韦、连花清瘟、清开灵…

日前,广东省卫健委印发《广东省流行性感冒防控方案(试行)的通知》(以下简称《方案》)。

广东援鄂战队:疫情面前,我们是爱人同志

一肩是家庭责任,一肩是工作责任。为了防控疫情,茂名首支支援湖北医疗队队员、我院急诊科副主任医师黎伟彬义无反顾远赴前线,舍弃“小家”为“大家”。他的心愿很

广东省报告新型冠状病毒感染的肺炎新增确诊病例5例,累计划151例

2020年1月27日0时至12时,广东省报告新型冠状病毒感染的肺炎新增确诊病例5例。其中广州市2例、梅州市2例、中山市1例。截至1月27日12时,广东省累计报告新型冠状病毒感染的肺炎确诊病例151例。确诊病例中,广州41例、深圳36例、珠海12例、汕头2例、佛山14例、韶关4例、梅州3例、惠州8例、汕尾1例、东莞2例、中山5例、阳江8例、湛江5例、肇庆4例、清远3例、揭阳3例。目前追踪到密切接触者

防止“救命药”短缺 广东拟实行短缺药品监测预警

记者丰西西报道:药品紧缺如何解决?如何确保药品供应服务安全高效?5月6日,广东省卫生健康委官网公布《广东省加强药品供应保障制度建设行动方案》(征求意见稿)(下称意见稿),5月9日前向社会征求意见。意见稿对备受关注的“用药”问题进行了详细明确。其中明确,将加强短缺药品预警应对,拟实行短缺药品监测预警、审核处置、清单管理制度,定期发布短缺药品清单并实行动态调整。对于临床必需、用量小或交易价格偏低、企业

广东规定:家庭医生为签约患者看病时长不低于8分钟

家庭医生是推动分级诊疗、缓解“看病难”的关键一环。针对推进家庭医生签约服务过程中,部分地区存在激励机制不完善、签约服务质量不高等问题,4月9日,广东省卫生健康委员会发布《关于进一步推进家庭医生签约服务政策措施落实的通知》(下简称《通知》),将通过建立家庭医生预约诊疗模式、提供中医药服务、建立家庭药师队伍等方式,推进家庭医生签约服务。亮点1:超七成签约服务费团队可自由支配为体现对家庭医生团队签约数量